193 reports of this reaction
1.4% of all TENOFOVIR DISOPROXIL FUMARATE TABLETS reports
#19 most reported adverse reaction
HEPATITIS B is the #19 most commonly reported adverse reaction for TENOFOVIR DISOPROXIL FUMARATE TABLETS, manufactured by Chartwell RX, LLC.. There are 193 FDA adverse event reports linking TENOFOVIR DISOPROXIL FUMARATE TABLETS to HEPATITIS B. This represents approximately 1.4% of all 14,129 adverse event reports for this drug.
Patients taking TENOFOVIR DISOPROXIL FUMARATE TABLETS who experience hepatitis b should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEPATITIS B is a less commonly reported adverse event for TENOFOVIR DISOPROXIL FUMARATE TABLETS, but still significant enough to appear in the safety profile.
In addition to hepatitis b, the following adverse reactions have been reported for TENOFOVIR DISOPROXIL FUMARATE TABLETS:
The following drugs have also been linked to hepatitis b in FDA adverse event reports:
HEPATITIS B has been reported as an adverse event in 193 FDA reports for TENOFOVIR DISOPROXIL FUMARATE TABLETS. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEPATITIS B accounts for approximately 1.4% of all adverse event reports for TENOFOVIR DISOPROXIL FUMARATE TABLETS, making it a notable side effect.
If you experience hepatitis b while taking TENOFOVIR DISOPROXIL FUMARATE TABLETS, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.